PKU Healthcare Corp. (000788.SZ): obtained pharmaceutical registration certificate for oral solution of levocetirizine dihydrochloride.

On July 9th, Gelunhui reported that PKU Healthcare Corp., Ltd. (stock code: 000788.SZ) recently received a Drug Registration Certificate issued by the National Medical Products Administration for Levocetirizine Hydrochloride Oral Solution (Specification: 5ml:2.5mg; 10ml:5mg). Levocetirizine hydrochloride is a second-generation H1 receptor antagonist and is the main medication for anti-histamine treatment of allergic rhinitis and skin diseases. Compared with cetirizine, levocetirizine is its optical isomer with fewer side effects. Indications include urticaria, allergic rhinitis, eczema, dermatitis, and pruritus.

Gelonghui FinanceJul 9 05:00 ET

As of May 31, 2024, the total number of shareholders of PKU Healthcare Corp. (000788.SZ) was 52,312.

PKU Healthcare Corp. (000788.SZ) stated on the investor platform that as of May 31, 2024, the total number of shareholders of the company is 52,312.

Gelonghui FinanceJun 17 04:19 ET

There's Reason For Concern Over PKU HealthCare Corp.,Ltd.'s (SZSE:000788) Price

PKU HealthCare Corp.,Ltd.'s (SZSE:000788) price-to-earnings (or "P/E") ratio of 41.2x might make it look like a sell right now compared to the market in China, where around half of the companies have

Simply Wall StJun 6 22:34 ET

Positive Earnings Growth Hasn't Been Enough to Get PKU HealthCareLtd (SZSE:000788) Shareholders a Favorable Return Over the Last Five Years

This week we saw the PKU HealthCare Corp.,Ltd. (SZSE:000788) share price climb by 14%. But that doesn't change the fact that the returns over the last five years have been less than pleasing. In f

Simply Wall StApr 26 18:19 ET

Peking University Pharmaceuticals (000788.SZ): Net profit of 44.46,900 yuan in the first quarter increased 163.66% year-on-year

On April 25, Ge Longhui Pharmaceutical (000788.SZ) released its first quarter report. Operating revenue was 490 million yuan, down 0.95% year on year, and net profit was 440.469 million yuan, up 163.66% year on year, after deducting non-net profit of 44.72 million yuan, up 163.68% year on year, with basic earnings of 0.0739 yuan per share.

Gelonghui FinanceApr 25 09:29 ET

Peking University Pharmaceuticals (000788.SZ): Mainly engaged in R&D, production and sales of chemical preparations and pharmaceutical distribution

Gelonghui, March 21丨Peking University Pharmaceutical (000788.SZ) said on the investor interactive platform that the company is mainly engaged in R&D, production and sales of chemical preparations and pharmaceutical distribution. The company's pharmaceutical manufacturing sector currently focuses on the three major fields of anti-infective, analgesic, and psychiatric drugs, mainly generic drugs.

Gelonghui FinanceMar 21 03:56 ET